{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T01:10:17Z","timestamp":1774314617513,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,5]]},"DOI":"10.7759\/cureus.100885","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T07:49:54Z","timestamp":1767685794000},"source":"Crossref","is-referenced-by-count":1,"title":["Adalimumab-Associated Sensory Neuropathy in a Young Patient With Spondyloarthritis: A Complication of Anti-tumor Necrosis Factor Therapy"],"prefix":"10.7759","author":[{"given":"Sushma","family":"Konnepati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaibhav","family":"Ingle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akash","family":"Pawar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Firoz","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agrata","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-021-08879-w","article-title":"Hypersensitivity and immune-related adverse events in biologic therapy","volume":"62","author":"Waldron JL","year":"2022","unstructured":"Waldron JL, Schworer SA, Kwan M. Hypersensitivity and immune-related adverse events in biologic therapy. Clin Rev Allergy Immunol. 2022, 62:413-31. 10.1007\/s12016-021-08879-w","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-013-2419-8","article-title":"Demyelinizing neurological disease after treatment with tumor necrosis factor alpha-inhibiting agents in a rheumatological outpatient clinic: description of six cases","volume":"33","author":"Theibich A","year":"2014","unstructured":"Theibich A, Dreyer L, Magyari M, Locht H. Demyelinizing neurological disease after treatment with tumor necrosis factor alpha-inhibiting agents in a rheumatological outpatient clinic: description of six cases. Clin Rheumatol. 2014, 33:719-23. 10.1007\/s10067-013-2419-8","journal-title":"Clin Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey D","year":"2008","unstructured":"Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008, 117:244-79. 10.1016\/j.pharmthera.2007.10.001","journal-title":"Pharmacol Ther"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxu102","article-title":"Anti-TNF therapy: past, present and future","volume":"27","author":"Monaco C","year":"2015","unstructured":"Monaco C, Nanchahal J, Taylor P, Feldmann M. Anti-TNF therapy: past, present and future. Int Immunol. 2015, 27:55-62. 10.1093\/intimm\/dxu102","journal-title":"Int Immunol"},{"key":"ref5","article-title":"Demyelination and inhibition of tumor necrosis factor (TNF)","volume":"22","author":"Magnano MD","year":"2004","unstructured":"Magnano MD, Robinson WH, Genovese MC. Demyelination and inhibition of tumor necrosis factor (TNF). Clin Exp Rheumatol. 2004, 22:134-40.","journal-title":"Clin Exp Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000720","article-title":"Peripheral neuropathy associated with anti-tumor necrosis factor therapy: a case report and review of the literature","volume":"25","author":"Mut SE","year":"2019","unstructured":"Mut SE, Tinazli M, Eker A, Akar S. Peripheral neuropathy associated with anti-tumor necrosis factor therapy: a case report and review of the literature. J Clin Rheumatol. 2019, 25:116-8. 10.1097\/RHU.0000000000000720","journal-title":"J Clin Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2011.1","article-title":"Monoclonal antibody therapy-associated neurological disorders","volume":"7","author":"Bosch X","year":"2011","unstructured":"Bosch X, Saiz A, Ramos-Casals M. Monoclonal antibody therapy-associated neurological disorders. Nat Rev Neurol. 2011, 7:165-72. 10.1038\/nrneurol.2011.1","journal-title":"Nat Rev Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60091409","article-title":"Neurological side effects of TNF-\u03b1 inhibitors revisited: a review of case reports","volume":"60","author":"Gogulescu A","year":"2024","unstructured":"Gogulescu A, Blidisel A, Soica C, et al.. Neurological side effects of TNF-\u03b1 inhibitors revisited: a review of case reports. Medicina (Kaunas). 2024, 60:10.3390\/medicina60091409","journal-title":"Medicina (Kaunas)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32835b1366","article-title":"Biologics-induced autoimmune diseases","volume":"25","author":"Perez-Alvarez R","year":"2013","unstructured":"Perez-Alvarez R, P\u00e9rez-de-Lis M, Ramos-Casals M. Biologics-induced autoimmune diseases. Curr Opin Rheumatol. 2013, 25:56-64. 10.1097\/BOR.0b013e32835b1366","journal-title":"Curr Opin Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.11","article-title":"Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-\u03b1-blocker therapy","volume":"66","author":"Lozeron P","year":"2009","unstructured":"Lozeron P, Denier C, Lacroix C, Adams D. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-\u03b1-blocker therapy. Arch Neurol. 2009, 66:490-7. 10.1001\/archneurol.2009.11","journal-title":"Arch Neurol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.31138\/mjr.32.2.96","article-title":"Biologic therapies and autoimmune phenomena","volume":"32","author":"Drosos AA","year":"2021","unstructured":"Drosos AA, Pelechas E, Kaltsonoudis E, Markatseli TE, Voulgari PV. Biologic therapies and autoimmune phenomena. Mediterr J Rheumatol. 2021, 32:96-103. 10.31138\/mjr.32.2.96","journal-title":"Mediterr J Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13175-0","article-title":"Peripheral neuropathies associated with anti-tnf-\u03b1 treatments: a systematic review and proposed recommendations","volume":"272","author":"Milella G","year":"2025","unstructured":"Milella G, Sozzo M, Lasorella P, Scannicchio S, Carlone S, Fornaro M, Defazio G. Peripheral neuropathies associated with anti-tnf-\u03b1 treatments: a systematic review and proposed recommendations. J Neurol. 2025, 272:10.1007\/s00415-025-13175-0","journal-title":"J Neurol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/402432-adalimumab-associated-sensory-neuropathy-in-a-young-patient-with-spondyloarthritis-a-complication-of-anti-tumor-necrosis-factor-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T07:50:05Z","timestamp":1767685805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/402432-adalimumab-associated-sensory-neuropathy-in-a-young-patient-with-spondyloarthritis-a-complication-of-anti-tumor-necrosis-factor-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.100885","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,5]]}}}